Enrolling by invitationNo phase
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
Key facts
- Where
- Boston, Cleveland, Delray Beach, Kansas City, New York, Salinas, Storrs, Washington D.C., West Chester, and Wynnewood, United StatesSee the 10 sites
Where in United States
- Beth Isreal Deaconess Medical CenterBoston, United StatesNo longer taking part
- Cleveland Clinic - Main CampusCleveland, United StatesNo longer taking part
- Delray Medical CenterDelray Beach, United StatesNo longer taking part
- Saint Luke's Hospital of Kansas CityKansas City, United StatesNo longer taking part
- NYU Langone Medical CenterNew York, United StatesNo longer taking part
- Salinas Valley Memorial HospitalSalinas, United StatesNo longer taking part
- University of ConnecticutStorrs, United StatesNo longer taking part
- MedStar Washington Hospital CenterWashington D.C., United StatesNo longer taking part
- University of PennsylvaniaWest Chester, United StatesNo longer taking part
- Main Line HealthWynnewood, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Endologix
- Trial code
- NCT06315023
- Record updated
- 12 May 2026
- Original description
The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis > 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.Read full original descriptionShow less
Prospective, Single Arm, Registry-based Study to Evaluate the Real-world Use of the DETOUR™ System in US Patients
The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis > 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.
Inclusion: -.
Exclusion: -.